- Home
- EMCG vs CTSO Comparison
EMCG vs CTSO Comparison
Compare EMCG & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMCG
- CTSO
- Stock Information
- Founded
- EMCG 2021
- CTSO 1997
- Country
- EMCG United States
- CTSO United States
- Employees
- EMCG N/A
- CTSO N/A
- Industry
- EMCG
- CTSO Medical/Dental Instruments
- Sector
- EMCG
- CTSO Health Care
- Exchange
- EMCG NYSE
- CTSO Nasdaq
- Market Cap
- EMCG 54.1M
- CTSO 61.3M
- IPO Year
- EMCG 2022
- CTSO N/A
- Fundamental
- Price
- EMCG N/A
- CTSO $1.03
- Analyst Decision
- EMCG
- CTSO Strong Buy
- Analyst Count
- EMCG 0
- CTSO 3
- Target Price
- EMCG N/A
- CTSO $4.67
- AVG Volume (30 Days)
- EMCG 169.0
- CTSO 74.6K
- Earning Date
- EMCG 01-01-0001
- CTSO 05-08-2025
- Dividend Yield
- EMCG N/A
- CTSO N/A
- EPS Growth
- EMCG N/A
- CTSO N/A
- EPS
- EMCG 0.23
- CTSO N/A
- Revenue
- EMCG N/A
- CTSO $35,594,520.00
- Revenue This Year
- EMCG N/A
- CTSO $18.72
- Revenue Next Year
- EMCG N/A
- CTSO $19.75
- P/E Ratio
- EMCG $52.75
- CTSO N/A
- Revenue Growth
- EMCG N/A
- CTSO 14.51
- 52 Week Low
- EMCG $11.19
- CTSO $0.70
- 52 Week High
- EMCG $13.39
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- EMCG 54.25
- CTSO 53.19
- Support Level
- EMCG $11.86
- CTSO $0.93
- Resistance Level
- EMCG $11.97
- CTSO $1.07
- Average True Range (ATR)
- EMCG 0.00
- CTSO 0.06
- MACD
- EMCG -0.00
- CTSO 0.01
- Stochastic Oscillator
- EMCG 81.82
- CTSO 71.43
About EMCG EMBRACE CHANGE ACQUISITION CORP
Embrace Change Acquisition Corp is a blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.